4-Aminopyridine improves clinical signs in multiple sclerosis

Area of Science:

• Neurology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system.
• Neurological deficits in MS are often attributed to impaired axonal function due to demyelination.

Purpose of the Study:

• To investigate the efficacy of 4-aminopyridine (4-AP) in ameliorating neurological deficits in patients with multiple sclerosis.
• To assess the functional state of potassium (K+) channels in demyelinated axons in humans.

Main Methods:

• A double-blind, placebo-controlled study involving 12 male patients with MS and 5 healthy male controls.
• Intravenous administration of 4-aminopyridine (4-AP) at doses ranging from 7 to 35 mg.
• Assessment of neurological function using static quantitative perimetry, flicker-fusion frequency, visual acuity, and videotaped neurological examinations.

Main Results:

• Ten out of twelve MS patients experienced mild to marked improvements in neurological functions.
• Specific improvements included enhanced vision in 7 patients, oculomotor function in 5, and motor function (power, coordination, gait) in 5.
• Improvements were dose-dependent, appearing within minutes of 4-AP administration and reversing within 2-4 hours; no significant effects were observed in the placebo group.

Conclusions:

• 4-aminopyridine (4-AP) can transiently alleviate multiple neurological deficits in patients with multiple sclerosis.
• The study provides evidence for the functional integrity of K+ channels in demyelinated central nervous system axons in humans.
• 4-AP offers substantial, albeit temporary, therapeutic benefits for selected MS patients.